Cargando…
Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy
BACKGROUND: End-stage renal disease (ESRD) is strongly associated with cardiovascular disease (CVD) risk. Advanced glycation endproducts (AGEs) and dicarbonyls, major precursors of AGEs, may contribute to the pathophysiology of CVD in ESRD. However, detailed data on the courses of AGEs and dicarbony...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577778/ https://www.ncbi.nlm.nih.gov/pubmed/33123361 http://dx.doi.org/10.1093/ckj/sfz099 |
_version_ | 1783598245138661376 |
---|---|
author | Martens, Remy J H Broers, Natascha J H Canaud, Bernard Christiaans, Maarten H L Cornelis, Tom Gauly, Adelheid Hermans, Marc M H Konings, Constantijn J A M van der Sande, Frank M Scheijen, Jean L J M Stifft, Frank Kooman, Jeroen P Schalkwijk, Casper G |
author_facet | Martens, Remy J H Broers, Natascha J H Canaud, Bernard Christiaans, Maarten H L Cornelis, Tom Gauly, Adelheid Hermans, Marc M H Konings, Constantijn J A M van der Sande, Frank M Scheijen, Jean L J M Stifft, Frank Kooman, Jeroen P Schalkwijk, Casper G |
author_sort | Martens, Remy J H |
collection | PubMed |
description | BACKGROUND: End-stage renal disease (ESRD) is strongly associated with cardiovascular disease (CVD) risk. Advanced glycation endproducts (AGEs) and dicarbonyls, major precursors of AGEs, may contribute to the pathophysiology of CVD in ESRD. However, detailed data on the courses of AGEs and dicarbonyls during the transition of ESRD patients to renal replacement therapy are lacking. METHODS: We quantified an extensive panel of free and protein-bound serum AGEs [N(∈)-(carboxymethyl)lysine (CML), N(∈)-(carboxyethyl)lysine (CEL), N(δ)-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine (MG-H1)], serum dicarbonyls [glyoxal (GO), methylglyoxal (MGO), 3-deoxyglucosone (3-DG)] and tissue AGE accumulation [estimated by skin autofluorescence (SAF)] in a combined cross-sectional and longitudinal observational study of patients with ESRD transitioning to dialysis or kidney transplantation (KTx), prevalent dialysis patients and healthy controls. Cross-sectional comparisons were performed with linear regression analyses, and courses following renal replacement therapy were analysed with linear mixed models. RESULTS: Free and protein-bound AGEs, dicarbonyls and SAF were higher in chronic kidney disease (CKD) Stage 5 non-dialysis (CKD 5-ND; n = 52) and CKD Stage 5 dialysis (CKD 5-D; n = 35) than in controls (n = 42). In addition, free AGEs, protein-bound CML, GO and SAF were even higher in CKD 5-D than in CKD5-ND. Similarly, following dialysis initiation (n = 43) free and protein-bound AGEs, and GO increased, whereas SAF remained similar. In contrast, following KTx (n = 21), free and protein-bound AGEs and dicarbonyls, but not SAF, markedly declined. CONCLUSIONS: AGEs and dicarbonyls accumulate in uraemia, which is even exaggerated by dialysis initiation. In contrast, KTx markedly reduces AGEs and dicarbonyls. Given their associations with CVD risk in high-risk populations, lowering AGE and dicarbonyl levels may be valuable. |
format | Online Article Text |
id | pubmed-7577778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75777782020-10-28 Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy Martens, Remy J H Broers, Natascha J H Canaud, Bernard Christiaans, Maarten H L Cornelis, Tom Gauly, Adelheid Hermans, Marc M H Konings, Constantijn J A M van der Sande, Frank M Scheijen, Jean L J M Stifft, Frank Kooman, Jeroen P Schalkwijk, Casper G Clin Kidney J Original Articles BACKGROUND: End-stage renal disease (ESRD) is strongly associated with cardiovascular disease (CVD) risk. Advanced glycation endproducts (AGEs) and dicarbonyls, major precursors of AGEs, may contribute to the pathophysiology of CVD in ESRD. However, detailed data on the courses of AGEs and dicarbonyls during the transition of ESRD patients to renal replacement therapy are lacking. METHODS: We quantified an extensive panel of free and protein-bound serum AGEs [N(∈)-(carboxymethyl)lysine (CML), N(∈)-(carboxyethyl)lysine (CEL), N(δ)-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine (MG-H1)], serum dicarbonyls [glyoxal (GO), methylglyoxal (MGO), 3-deoxyglucosone (3-DG)] and tissue AGE accumulation [estimated by skin autofluorescence (SAF)] in a combined cross-sectional and longitudinal observational study of patients with ESRD transitioning to dialysis or kidney transplantation (KTx), prevalent dialysis patients and healthy controls. Cross-sectional comparisons were performed with linear regression analyses, and courses following renal replacement therapy were analysed with linear mixed models. RESULTS: Free and protein-bound AGEs, dicarbonyls and SAF were higher in chronic kidney disease (CKD) Stage 5 non-dialysis (CKD 5-ND; n = 52) and CKD Stage 5 dialysis (CKD 5-D; n = 35) than in controls (n = 42). In addition, free AGEs, protein-bound CML, GO and SAF were even higher in CKD 5-D than in CKD5-ND. Similarly, following dialysis initiation (n = 43) free and protein-bound AGEs, and GO increased, whereas SAF remained similar. In contrast, following KTx (n = 21), free and protein-bound AGEs and dicarbonyls, but not SAF, markedly declined. CONCLUSIONS: AGEs and dicarbonyls accumulate in uraemia, which is even exaggerated by dialysis initiation. In contrast, KTx markedly reduces AGEs and dicarbonyls. Given their associations with CVD risk in high-risk populations, lowering AGE and dicarbonyl levels may be valuable. Oxford University Press 2019-08-28 /pmc/articles/PMC7577778/ /pubmed/33123361 http://dx.doi.org/10.1093/ckj/sfz099 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Martens, Remy J H Broers, Natascha J H Canaud, Bernard Christiaans, Maarten H L Cornelis, Tom Gauly, Adelheid Hermans, Marc M H Konings, Constantijn J A M van der Sande, Frank M Scheijen, Jean L J M Stifft, Frank Kooman, Jeroen P Schalkwijk, Casper G Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy |
title | Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy |
title_full | Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy |
title_fullStr | Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy |
title_full_unstemmed | Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy |
title_short | Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy |
title_sort | advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577778/ https://www.ncbi.nlm.nih.gov/pubmed/33123361 http://dx.doi.org/10.1093/ckj/sfz099 |
work_keys_str_mv | AT martensremyjh advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT broersnataschajh advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT canaudbernard advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT christiaansmaartenhl advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT cornelistom advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT gaulyadelheid advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT hermansmarcmh advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT koningsconstantijnjam advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT vandersandefrankm advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT scheijenjeanljm advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT stifftfrank advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT koomanjeroenp advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy AT schalkwijkcasperg advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy |